Please assess the completion status of the following clinical trial:

Trial Title: Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years of age~* Ability to understand and sign informed consent~* Biopsy-proven diagnosis of previous cancer (solid or hematologic disease)~* Participants must be diagnosed with active malignancy, defined as the presence of metastatic disease; or patient undergoing curative treatment during cancer treatment, regardless of the therapeutic modality.~* Confirmed diagnosis of COVID-19 by the presence of a positive PCR test or positive serological test and / or diagnosis presumed by the presence of flu-like symptoms associated to suggestive findings on CT scan.~* ECOG performance status 0 to 2~* Patients must have an assessment of adequate organ function within 28 days prior to enrollment, evidenced by:~  * Hemoglobin ≥ 9.0 g / dL~ * Leukometry\> 2,000 / mm3~ * Absolute neutrophil count ≥ 1,500 / mm3~ * Platelet count ≥ 100,000 / mm3~ * Creatinine clearance ≥ 30 mL / min. Creatinine clearance (CrCl) should be calculated according to the Cockcroft-Gault formula.~ * Total bilirubin \<3 x the upper limit of normal (ULN), except for patients with known Gilbert's syndrome.~ * Aspartate aminotransaminase (AST) \<3.0 x LSN.~ * Alanine aminotransaminase (ALT) \<3.0 x ULN.~Exclusion Criteria:~* Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin receptor blocker (ARB).~* Patients who presents with severe conditions at the time of diagnosis requiring ICU admission.~* Prior reaction or intolerance to an ARB or ACE inhibitor.~* Blood pressure less than 110/70 mmHg at presentation~* Potassium greater than 5.0 mEq / L~* Pregnancy or breastfeeding~* Prior reaction to Ivermectin.~* Patient currently enrolled in another research protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARM A: Placebo (Type: PLACEBO_COMPARATOR): Patients will receive ivermectin-placebo single dose on the day of confirmed diagnosis of COVID-19, followed by losartan-placebo daily for 15 days.
- ARM B: Ivermectin plus losartan (Type: EXPERIMENTAL): Patients will receive a single dose of 12mg of ivermectin on the day of the confirmed diagnosis of COVID-19, followed by losartan 50mg orally once daily for 15 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).